immatics biotechnologies GmbH NASDAQ:IMTXW

immatics biotechnologies GmbH stock price today

$0.001
-0.19
-99.7%
Financial Health
0
1
2
3
4
5
6
7
8
9

immatics biotechnologies GmbH stock price monthly change

-94.08%
month

immatics biotechnologies GmbH stock price quarterly change

-94.08%
quarter

immatics biotechnologies GmbH stock price yearly change

-94.09%
year

immatics biotechnologies GmbH key metrics

Market Cap
635.91M
Enterprise value
N/A
P/E
N/A
EV/Sales
N/A
EV/EBITDA
N/A
Price/Sales
N/A
Price/Book
N/A
PEG ratio
N/A
EPS
-0.98
Revenue
74.64M
EBITDA
-68.81M
Income
-80.31M
Revenue Q/Q
210.81%
Revenue Y/Y
-6.36%
Profit margin
0%
Oper. margin
0%
Gross margin
0%
EBIT margin
0%
EBITDA margin
-92.18%
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

immatics biotechnologies GmbH stock price history

immatics biotechnologies GmbH stock forecast

immatics biotechnologies GmbH financial statements

immatics biotechnologies GmbH (NASDAQ:IMTXW): Profit margin
Jun 2023 22.35M -24.61M -110.09%
Sep 2023 5.92M -26.48M -447%
Dec 2023 15.92M -26.14M -164.24%
Mar 2024 30.44M -3.07M -10.09%
immatics biotechnologies GmbH (NASDAQ:IMTXW): Debt to assets
Jun 2023 410189000 191.97M 46.8%
Sep 2023 437450000 189.69M 43.36%
Dec 2023 509965000 284.88M 55.86%
Mar 2024 653730305 252.57M 38.64%
immatics biotechnologies GmbH (NASDAQ:IMTXW): Cash Flow
Jun 2023 -6.60M -16.83M 36.45M
Sep 2023 -30.52M -70.57M 49.90M
Dec 2023 79.07M 59.73M -972K
Mar 2024 -32.79M -243.24M 175.67M

immatics biotechnologies GmbH alternative data

immatics biotechnologies GmbH (NASDAQ:IMTXW): Employee count
Jan 2024 433
Feb 2024 433
Mar 2024 432
Apr 2024 432
May 2024 432
Jun 2024 432
Jul 2024 432

immatics biotechnologies GmbH other data

Patent
Application
Filling date: 13 May 2022 Issue date: 8 Sep 2022
Application
Filling date: 3 Mar 2022 Issue date: 8 Sep 2022
Grant
Filling date: 18 Mar 2022 Issue date: 6 Sep 2022
Grant
Filling date: 24 Sep 2021 Issue date: 6 Sep 2022
Grant
Filling date: 27 Aug 2021 Issue date: 6 Sep 2022
Grant
Filling date: 5 Dec 2019 Issue date: 6 Sep 2022
Application
Filling date: 2 May 2022 Issue date: 1 Sep 2022
Grant
Filling date: 11 Feb 2022 Issue date: 30 Aug 2022
Grant
Filling date: 10 Apr 2018 Issue date: 30 Aug 2022
Application
Filling date: 6 May 2022 Issue date: 25 Aug 2022
  • What's the price of immatics biotechnologies GmbH stock today?

    One share of immatics biotechnologies GmbH stock can currently be purchased for approximately $0.

  • When is immatics biotechnologies GmbH's next earnings date?

    Unfortunately, immatics biotechnologies GmbH's (IMTXW) next earnings date is currently unknown.

  • Does immatics biotechnologies GmbH pay dividends?

    No, immatics biotechnologies GmbH does not pay dividends.

  • How much money does immatics biotechnologies GmbH make?

    immatics biotechnologies GmbH has a market capitalization of 635.91M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 68.76% to 54M US dollars.

  • What is immatics biotechnologies GmbH's stock symbol?

    immatics biotechnologies GmbH is traded on the NASDAQ under the ticker symbol "IMTXW".

  • What is immatics biotechnologies GmbH's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of immatics biotechnologies GmbH?

    Shares of immatics biotechnologies GmbH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • How many employees does immatics biotechnologies GmbH have?

    As Jul 2024, immatics biotechnologies GmbH employs 432 workers.

  • When immatics biotechnologies GmbH went public?

    immatics biotechnologies GmbH is publicly traded company for more then 5 years since IPO on 2 Jul 2020.

  • What is immatics biotechnologies GmbH's official website?

    The official website for immatics biotechnologies GmbH is immatics.com.

  • How can i contact immatics biotechnologies GmbH?

    immatics biotechnologies GmbH can be reached via phone at +49 7071 53970.

immatics biotechnologies GmbH company profile:

immatics biotechnologies GmbH

immatics.com
Exchange:

NASDAQ

Full time employees:

542

Industry:

Biotechnology

Sector:

Healthcare

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401, which is in Phase 1b clinical trial; and IMA402 and IMA403, which are in preclinical stages. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.

Paul-Ehrlich-Strasse 15
Tübingen, 72076

CIK: 0001809196
ISIN: NL0015285958
CUSIP: N44445117